Exelixis Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for EXELIXIS, and what generic alternatives to EXELIXIS drugs are available?
EXELIXIS has two approved drugs.
There are eleven US patents protecting EXELIXIS drugs.
There are two hundred and three patent family members on EXELIXIS drugs in thirty-three countries and nineteen supplementary protection certificates in sixteen countries.
Summary for Exelixis
| International Patents: | 203 |
| US Patents: | 11 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Exelixis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-001 | Nov 29, 2012 | RX | Yes | Yes | 9,717,720 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 11,298,349 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | 9,724,342 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 11,098,015 | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Exelixis Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101733773 | See Plans and Pricing |
| Japan | 5677318 | See Plans and Pricing |
| New Zealand | 594594 | See Plans and Pricing |
| Georgia, Republic of | P20217235 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Exelixis Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2213661 | 92508 | Luxembourg | See Plans and Pricing | PRODUCT NAME: CABOZANTINIB ET TOUTES LES FORMES THERAPEUTIQUEMENT EQUIVALENTES QUI EN DERIVENT TELLES QUE PROTEGEES PAR LE BREVET DE BASE, Y COMPRIS LES SELS PHARMACEUTIQUEMENT ACCEPTABLES. FIRST REGISTRATION: 20140326 |
| 2213661 | SPC/GB14/052 | United Kingdom | See Plans and Pricing | PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/13/890/001-006 20140326 |
| 2213661 | 583 | Finland | See Plans and Pricing | |
| 2213661 | 2014/052 | Ireland | See Plans and Pricing | PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
